Analytomix LLC

Analytomix LLC is a biotechnology company that has developed a modular platform called AptaLinx, designed for precision cancer drug delivery. The technology operates on the concept of using the tumor as a trigger for drug release. The platform utilizes FDA-approved antibodies as targeting vehicles to bind specifically to cancer cell markers, delivering a therapeutic system directly to the site. Once the antibody reaches its target, a nucleic acid aptamer—the release mechanism—detaches from the antibody, triggering the release of the therapeutic payload. This payload can be covalently linked directly to the aptamer or attached to a lipid nanoparticle, similar to technology used in mRNA vaccines. By leveraging established antibodies and chemotherapy drugs, the platform aims to minimize regulatory risks and accelerate the transition from research to clinical application.

The company focuses on developing smart molecules intended for diagnostic tests and advanced cancer treatments, with the goal of improving survivorship and patient outcomes. The team comprises scientists with diverse expertise in biomedical sciences, molecular biology, and cancer biology. Based in Torrance, California, the company emphasizes a collaborative approach to research and business development, working toward partnerships that can scale its precision medicine technology for clinical use. Analytomix was co-founded by Mohammad S. Atefi, who serves as CEO, and Carlos Pereira, with the company's activities centered on advancing these proprietary therapeutic platforms.